Trial intelligence / Profile preview

Phase II study of MK-5172 + MK-8742 + ribavirin in chronic HCV patients who failed prior DAA therapy

2013-004213-41Phase 2Completed

Sponsor

Merck & Co.

Start

Apr 2014

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Countries

1